Long-term outcome of percutaneous transluminal renal angioplasty in transplant renal artery stenosis
Background Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous transluminal renal angioplasty (PTRA) and PTRA with stenting (PTRAS). Accordingly, this study aimed to investigate the 1-year cli...
Saved in:
Published in | BMC cardiovascular disorders Vol. 21; no. 1 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
BioMed Central Ltd
26.04.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous transluminal renal angioplasty (PTRA) and PTRA with stenting (PTRAS). Accordingly, this study aimed to investigate the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in patients diagnosed with TRAS at Thailand's largest national tertiary referral center. Methods This single-center retrospective study included kidney transplant patients treated for TRAS during January 2001 to June 2019. Clinical success was defined as (1) increase in estimated glomerular filtration rate (eGFR) > 15%, or (2) reduction in mean arterial pressure (MAP) > 15% with no decrease in antihypertensive medication, or no reduction in MAP or reduction in MAP < 15% with decrease in antihypertensive medication. Incidence of kidney transplant graft failure and transplant renal artery stenosis were also collected. Results Sixty-five cases of TRAS were identified from 1072 patients who underwent kidney transplantation. The majority (98.5%) had end-to-side anastomosis technique. Thirty-four patients had PTRA, while 31 patients had PTRAS. One-year clinical success according to renal outcome and BP reduction was 78.5% and 49.2%, respectively. Both renal outcome (79.4% vs. 77.4%, p = 0.845) and BP reduction (40.6% vs. 58.1%, p = 0.166) at 1 year were similar between the PTRA and PTRAS groups. Compared between PTRA and PTRAS, event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher for PTRAS at 1 year (82.4% vs. 100%, p = 0.025), but not significantly different at 10 years (73.5% vs. 71%, p = 0.818). Conclusions We demonstrated the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in TRAS patients. One-year clinical success was found to be similar between groups. Event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher in PTRAS at 1 year, but similar between groups at 10 years. Trial registration Thai Clinical Trials Registry, TCTR20200626002. Registered 26 June 2020--Retrospectively registered, Keywords: Percutaneous transluminal renal angioplasty (PTRA), Percutaneous transluminal renal angioplasty with stenting (PTRAS), Transplant renal artery stenosis (TRAS), Long-term outcome |
---|---|
AbstractList | Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous transluminal renal angioplasty (PTRA) and PTRA with stenting (PTRAS). Accordingly, this study aimed to investigate the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in patients diagnosed with TRAS at Thailand's largest national tertiary referral center. This single-center retrospective study included kidney transplant patients treated for TRAS during January 2001 to June 2019. Clinical success was defined as (1) increase in estimated glomerular filtration rate (eGFR) > 15%, or (2) reduction in mean arterial pressure (MAP) > 15% with no decrease in antihypertensive medication, or no reduction in MAP or reduction in MAP < 15% with decrease in antihypertensive medication. Incidence of kidney transplant graft failure and transplant renal artery stenosis were also collected. Sixty-five cases of TRAS were identified from 1072 patients who underwent kidney transplantation. The majority (98.5%) had end-to-side anastomosis technique. Thirty-four patients had PTRA, while 31 patients had PTRAS. One-year clinical success according to renal outcome and BP reduction was 78.5% and 49.2%, respectively. Both renal outcome (79.4% vs. 77.4%, p = 0.845) and BP reduction (40.6% vs. 58.1%, p = 0.166) at 1 year were similar between the PTRA and PTRAS groups. Compared between PTRA and PTRAS, event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher for PTRAS at 1 year (82.4% vs. 100%, p = 0.025), but not significantly different at 10 years (73.5% vs. 71%, p = 0.818). We demonstrated the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in TRAS patients. One-year clinical success was found to be similar between groups. Event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher in PTRAS at 1 year, but similar between groups at 10 years. Background Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous transluminal renal angioplasty (PTRA) and PTRA with stenting (PTRAS). Accordingly, this study aimed to investigate the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in patients diagnosed with TRAS at Thailand's largest national tertiary referral center. Methods This single-center retrospective study included kidney transplant patients treated for TRAS during January 2001 to June 2019. Clinical success was defined as (1) increase in estimated glomerular filtration rate (eGFR) > 15%, or (2) reduction in mean arterial pressure (MAP) > 15% with no decrease in antihypertensive medication, or no reduction in MAP or reduction in MAP < 15% with decrease in antihypertensive medication. Incidence of kidney transplant graft failure and transplant renal artery stenosis were also collected. Results Sixty-five cases of TRAS were identified from 1072 patients who underwent kidney transplantation. The majority (98.5%) had end-to-side anastomosis technique. Thirty-four patients had PTRA, while 31 patients had PTRAS. One-year clinical success according to renal outcome and BP reduction was 78.5% and 49.2%, respectively. Both renal outcome (79.4% vs. 77.4%, p = 0.845) and BP reduction (40.6% vs. 58.1%, p = 0.166) at 1 year were similar between the PTRA and PTRAS groups. Compared between PTRA and PTRAS, event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher for PTRAS at 1 year (82.4% vs. 100%, p = 0.025), but not significantly different at 10 years (73.5% vs. 71%, p = 0.818). Conclusions We demonstrated the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in TRAS patients. One-year clinical success was found to be similar between groups. Event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher in PTRAS at 1 year, but similar between groups at 10 years. Trial registration Thai Clinical Trials Registry, TCTR20200626002. Registered 26 June 2020--Retrospectively registered, Keywords: Percutaneous transluminal renal angioplasty (PTRA), Percutaneous transluminal renal angioplasty with stenting (PTRAS), Transplant renal artery stenosis (TRAS), Long-term outcome |
Audience | Academic |
Author | Tongdee, Thongtum Vongwiwatana, Attapong Anusonadisai, Kawin Pongakasira, Rungtiwa Chaipruckmalakarn, Thunyarat Wongpraparut, Nattawut Premasathian, Nalinee Jaspttananon, Archan |
Author_xml | – sequence: 1 fullname: Wongpraparut, Nattawut – sequence: 2 fullname: Chaipruckmalakarn, Thunyarat – sequence: 3 fullname: Tongdee, Thongtum – sequence: 4 fullname: Jaspttananon, Archan – sequence: 5 fullname: Vongwiwatana, Attapong – sequence: 6 fullname: Premasathian, Nalinee – sequence: 7 fullname: Anusonadisai, Kawin – sequence: 8 fullname: Pongakasira, Rungtiwa |
BookMark | eNptUMlqwzAQFSWFJml_oCdBz2o1ki3ZxxC6QaCX3IOsxajYUrDkQ_6-CmkhhzLMm-3NY5gVWoQYLEKPQJ8BGvGSgDWSEcqgOIWaVDdoCZUEwpiAxVV-h1YpfVMKsqHtEpldDD3JdhpxnLOOo8XR4aOd9JxVsHFOOE8qpGEefVADnuwZVeh9PA4q5RP24cIoZch_86konnDKNsTk0z26dWpI9uE3rtH-7XW__SC7r_fP7WZHeiEb4sBQWbW16hwwraw0tqWGO2GkOYOuapCKc2i5dtx1TVdzC1KCYKA7qPkaPV1kezXYgw8ulsP06JM-bISACpqaNYX1_A-rmLGj1-Wtzpf-1cIP-nNruw |
ContentType | Journal Article |
Copyright | COPYRIGHT 2021 BioMed Central Ltd. |
Copyright_xml | – notice: COPYRIGHT 2021 BioMed Central Ltd. |
DOI | 10.1186/s12872-021-02015-4 |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2261 |
ExternalDocumentID | A661418528 |
GeographicLocations | Thailand |
GeographicLocations_xml | – name: Thailand |
GroupedDBID | --- -A0 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABUWG ABVAZ ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ AEAQA AENEX AFGXO AFKRA AFNRJ AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CS3 DIK DU5 E3Z EBD EBS ECGQY EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB |
ID | FETCH-LOGICAL-g678-f1d07495abf12cae7de90d3f6d7df6d7c4517a33193cf3fb8b53e1771621cb153 |
IEDL.DBID | M48 |
ISSN | 1471-2261 |
IngestDate | Thu Feb 22 23:27:33 EST 2024 Wed Jan 10 04:26:02 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-g678-f1d07495abf12cae7de90d3f6d7df6d7c4517a33193cf3fb8b53e1771621cb153 |
ParticipantIDs | gale_infotracmisc_A661418528 gale_infotracacademiconefile_A661418528 |
PublicationCentury | 2000 |
PublicationDate | 20210426 |
PublicationDateYYYYMMDD | 2021-04-26 |
PublicationDate_xml | – month: 04 year: 2021 text: 20210426 day: 26 |
PublicationDecade | 2020 |
PublicationTitle | BMC cardiovascular disorders |
PublicationYear | 2021 |
Publisher | BioMed Central Ltd |
Publisher_xml | – name: BioMed Central Ltd |
SSID | ssj0017809 |
Score | 2.2927976 |
Snippet | Background Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between... Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous... |
SourceID | gale |
SourceType | Aggregation Database |
SubjectTerms | Angioplasty Care and treatment Comparative analysis Diagnosis Methods Patient outcomes Renal artery obstruction |
Title | Long-term outcome of percutaneous transluminal renal angioplasty in transplant renal artery stenosis |
Volume | 21 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS8MwEA5zgvgi_sTpHHkQfIqaNG3SB5EpjiHOB9lg-DLSNBkDSWfbgfvvvdQOJwxfDkrSUvLl7r4jlzuELgNtjdSMExXwlICHkCQxsSEAvTZhpCNZ1ZkdvEb9EX8eh-MGWrU7qhew2Bja-X5So_zj-utzeQ8Kf1cpvIxuCrCxghGfbADkh4aEb6Ft5gtz-VQ-_nuqIGSV8kHBIBOgHXR1iWbjN2obveZtevtor6aJuPuD6wFqGHeIdgb1QfgRSl8yNyXerOJsUcKuMTizeG5yvQC2ZyCcx6X3QmB6fNsrnBsvlZvOsjnw5XKJZ-5nBjy6cjXu8zuXGIB3WTErjtGw9zR87JO6YQKZgs8hlqZACOJQJZYyrYxITXybBjZKReqF5iEVKgClA4QCm8gkDAwVvoYU1QmYvhPUdJkzpwhzy5UQljOlDA95pKyWTFnGE3B1Oopb6MovzsTjAj-rVZ3MD2_7elKTrnf7_l62bKH2n5mwe_Xa8Nn_w-dol1WYcMKiNmqW-cJcAAsok04VPXcqgEG-Pbx_AzIqsds |
link.rule.ids | 315,783,787,867,24332,27938,27939 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+outcome+of+percutaneous+transluminal+renal+angioplasty+in+transplant+renal+artery+stenosis&rft.jtitle=BMC+cardiovascular+disorders&rft.au=Wongpraparut%2C+Nattawut&rft.au=Chaipruckmalakarn%2C+Thunyarat&rft.au=Tongdee%2C+Thongtum&rft.au=Jaspttananon%2C+Archan&rft.date=2021-04-26&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2261&rft.eissn=1471-2261&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12872-021-02015-4&rft.externalDocID=A661418528 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2261&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2261&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2261&client=summon |